4L4Y
| |
4L4Z
| Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition | Descriptor: | (2S)-2,3,3-trihydroxy-4-oxopentyl dihydrogen phosphate, Transcriptional regulator LsrR | Authors: | Ryu, K.S, Ha, J.H, Eo, Y. | Deposit date: | 2013-06-10 | Release date: | 2013-11-06 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (2.3 Å) | Cite: | Crystal Structures of the LsrR Proteins Complexed with Phospho-AI-2 and Two Signal-Interrupting Analogues Reveal Distinct Mechanisms for Ligand Recognition. J.Am.Chem.Soc., 135, 2013
|
|
4L50
| Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition | Descriptor: | (2S)-2,3,3-trihydroxy-6-methyl-4-oxoheptyl dihydrogen phosphate, Transcriptional regulator LsrR | Authors: | Ryu, K.S, Ha, J.H, Eo, Y. | Deposit date: | 2013-06-10 | Release date: | 2013-11-06 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (2.1 Å) | Cite: | Crystal Structures of the LsrR Proteins Complexed with Phospho-AI-2 and Two Signal-Interrupting Analogues Reveal Distinct Mechanisms for Ligand Recognition. J.Am.Chem.Soc., 135, 2013
|
|
4L5I
| |
4L51
| |
4L5J
| |
5YA2
| Crystal structure of LsrK-HPr complex with ADP | Descriptor: | ADENOSINE-5'-DIPHOSPHATE, Autoinducer-2 kinase, HEXANE-1,6-DIOL, ... | Authors: | Ryu, K.S, Ha, J.H. | Deposit date: | 2017-08-30 | Release date: | 2018-07-11 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (2.701 Å) | Cite: | Evidence of link between quorum sensing and sugar metabolism inEscherichia colirevealed via cocrystal structures of LsrK and HPr Sci Adv, 4, 2018
|
|
5YA1
| crystal structure of LsrK-HPr complex with ATP | Descriptor: | ADENOSINE-5'-TRIPHOSPHATE, Autoinducer-2 kinase, HEXANE-1,6-DIOL, ... | Authors: | Ryu, K.S, Ha, J.H. | Deposit date: | 2017-08-29 | Release date: | 2018-07-11 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (2.701 Å) | Cite: | Evidence of link between quorum sensing and sugar metabolism inEscherichia colirevealed via cocrystal structures of LsrK and HPr Sci Adv, 4, 2018
|
|
5YA0
| Crystal structure of LsrK and HPr complex | Descriptor: | Autoinducer-2 kinase, HEXANE-1,6-DIOL, PHOSPHATE ION, ... | Authors: | Ryu, K.S, Ha, J.H. | Deposit date: | 2017-08-29 | Release date: | 2018-07-11 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (2.997 Å) | Cite: | Evidence of link between quorum sensing and sugar metabolism inEscherichia colirevealed via cocrystal structures of LsrK and HPr Sci Adv, 4, 2018
|
|
7ER9
| Crystal structure of human Biliverdin IX-beta reductase B with Febuxostat (TEI) | Descriptor: | 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.45 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ERE
| Crystal structure of human Biliverdin IX-beta reductase B with Pyrantel Pamoate (PPA) | Descriptor: | 4-[(3-carboxy-2-oxidanyl-naphthalen-1-yl)methyl]-3-oxidanyl-naphthalene-2-carboxylic acid, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ER6
| Crystal structure of human Biliverdin IX-beta reductase B | Descriptor: | Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, SULFATE ION | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ER7
| Crystal structure of hyman Biliverdin IX-beta reductase B with Tamibarotene (A80) | Descriptor: | 4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbamoyl]benzoic acid, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ERC
| Crystal structure of human Biliverdin IX-beta reductase B with Deferasirox (ICL) | Descriptor: | 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.5 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ERD
| Crystal structure of human Biliverdin IX-beta reductase B with Flunixin Meglumin (FMG) | Descriptor: | 2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]pyridine-3-carboxylic acid, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ER8
| Crystal structure of human Biliverdin IX-beta reductase B with Sulfasalazine (SAS) | Descriptor: | 2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.45 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ERB
| Crystal structure of human Biliverdin IX-beta reductase B with Ataluren (PTC) | Descriptor: | 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.5 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
7ERA
| Crystal structure of human Biliverdin IX-beta reductase B with Olsalazine Sodium (OSS) | Descriptor: | 5-[(E)-(3-carboxy-4-oxidanyl-phenyl)diazenyl]-2-oxidanyl-benzoic acid, Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... | Authors: | Griesinger, C, Lee, D, Ryu, K.S, Kim, M, Ha, J.H. | Deposit date: | 2021-05-06 | Release date: | 2022-01-19 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.35 Å) | Cite: | Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65, 2022
|
|
6A6P
| Crystal Structure of Peroxisome Proliferator-Activated Receptor Delta (PPARd)LBD in Complex with DN003316 | Descriptor: | 3,6,9,12,15,18,21,24,27,30,33,36,39-TRIDECAOXAHENTETRACONTANE-1,41-DIOL, Peroxisome proliferator-activated receptor delta, heptyl beta-D-glucopyranoside, ... | Authors: | Chin, J.W, Cho, S.J, Song, J.Y, Ha, J.H. | Deposit date: | 2018-06-29 | Release date: | 2019-07-10 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (2.1 Å) | Cite: | Crystal Structure of Peroxisome Proliferator-Activated Receptor Delta (PPARd)LBD in Complex with DN003316 To Be Published
|
|
2MPS
| |
7CM0
| Crystal structure of a glutaminyl cyclase in complex with NHV-1009 | Descriptor: | 1-(cyclopentylmethyl)-1-[3-methoxy-4-(2-morpholin-4-ylethoxy)phenyl]-3-[3-(5-methylimidazol-1-yl)propyl]urea, Glutaminyl-peptide cyclotransferase, ZINC ION | Authors: | Lee, J.W, Song, J.Y, Jang, T.H, Ha, J.H. | Deposit date: | 2020-07-23 | Release date: | 2021-12-22 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.2 Å) | Cite: | Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design. Eur.J.Med.Chem., 226, 2021
|
|
3Q3F
| Engineering Domain-Swapped Binding Interfaces by Mutually Exclusive Folding: Insertion of Ubiquitin into position 103 of Barnase | Descriptor: | Ribonuclease/Ubiquitin chimeric protein, SULFATE ION | Authors: | Ha, J.-H, Karchin, J.M, Walker-Kopp, N, Huang, L.-S, Berry, E.A, Loh, S.N. | Deposit date: | 2010-12-21 | Release date: | 2012-01-25 | Last modified: | 2023-09-13 | Method: | X-RAY DIFFRACTION (2.169 Å) | Cite: | Engineering domain-swapped binding interfaces by mutually exclusive folding. J.Mol.Biol., 416, 2012
|
|